Auris Huen

1.4k total citations
75 papers, 841 citations indexed

About

Auris Huen is a scholar working on Dermatology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Auris Huen has authored 75 papers receiving a total of 841 indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Dermatology, 38 papers in Pathology and Forensic Medicine and 33 papers in Oncology. Recurrent topics in Auris Huen's work include Cutaneous lymphoproliferative disorders research (44 papers), Lymphoma Diagnosis and Treatment (32 papers) and CAR-T cell therapy research (20 papers). Auris Huen is often cited by papers focused on Cutaneous lymphoproliferative disorders research (44 papers), Lymphoma Diagnosis and Treatment (32 papers) and CAR-T cell therapy research (20 papers). Auris Huen collaborates with scholars based in United States, Italy and France. Auris Huen's co-authors include Alain H. Rook, Madeleine Duvic, Ellen J. Kim, Michael T. Tetzlaff, Carlos A. Torres‐Cabala, Priyadharsini Nagarajan, Víctor G. Prieto, Jonathan L. Curry, Phyu P. Aung and Ray Hachem and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Auris Huen

63 papers receiving 831 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Auris Huen United States 15 355 327 324 225 162 75 841
Jeane P. Hester United States 19 91 0.3× 96 0.3× 282 0.9× 251 1.1× 101 0.6× 51 907
Chih-Hsun Yang Taiwan 9 303 0.9× 317 1.0× 149 0.5× 147 0.7× 101 0.6× 17 925
Benedetta Terziroli Beretta‐Piccoli Switzerland 19 166 0.5× 153 0.5× 73 0.2× 122 0.5× 786 4.9× 49 1.5k
Masaki Tominaga Japan 17 87 0.2× 53 0.2× 110 0.3× 176 0.8× 179 1.1× 68 1.1k
É. Bégon France 14 297 0.8× 160 0.5× 21 0.1× 292 1.3× 170 1.0× 49 714
C Poynton United Kingdom 12 60 0.2× 227 0.7× 192 0.6× 145 0.6× 109 0.7× 20 592
P. Papanastasiou Switzerland 13 110 0.3× 74 0.2× 536 1.7× 201 0.9× 54 0.3× 27 1.1k
G. B. Vogelsang United States 17 44 0.1× 81 0.2× 267 0.8× 405 1.8× 101 0.6× 28 1.2k
Steve Schey United Kingdom 17 32 0.1× 307 0.9× 534 1.6× 258 1.1× 256 1.6× 45 1.4k
Vincent Descamps France 9 193 0.5× 239 0.7× 80 0.2× 252 1.1× 268 1.7× 13 1.3k

Countries citing papers authored by Auris Huen

Since Specialization
Citations

This map shows the geographic impact of Auris Huen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Auris Huen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Auris Huen more than expected).

Fields of papers citing papers by Auris Huen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Auris Huen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Auris Huen. The network helps show where Auris Huen may publish in the future.

Co-authorship network of co-authors of Auris Huen

This figure shows the co-authorship network connecting the top 25 collaborators of Auris Huen. A scholar is included among the top collaborators of Auris Huen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Auris Huen. Auris Huen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Torres‐Cabala, Carlos A., Auris Huen, Guilin Tang, et al.. (2025). Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma with novel FGFR1 fusion treated with pemigatinib. Blood Advances. 9(8). 1786–1790.
2.
Fang, Penny, Sonal S. Noticewala, Susan Wu, et al.. (2024). Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?. Advances in Radiation Oncology. 9(12). 101650–101650.
3.
Marques‐Piubelli, Mario L., Courtney W. Hudgens, Rossana Lazcano, et al.. (2024). Differential Upregulation of Th1/Th17-Associated Proteins and PD-L1 in Granulomatous Mycosis Fungoides. Cells. 13(5). 419–419.
4.
Wu, Susan, Jie Xu, Penny Fang, et al.. (2024). Radiotherapy in the treatment of primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder. International Journal of Dermatology. 64(2). 385–389.
5.
Porcu, Pierluigi, C. Ram‐Wolff, Youn H. Kim, et al.. (2024). Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Results from the TELLOMAK phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 7082–7082. 4 indexed citations
6.
Kundu, Suprateek, et al.. (2023). Management strategies and survival in cutaneous B-cell lymphoma: A population based study. JAAD International. 13. 28–29.
7.
Wu, Susan, Penny Fang, Sairah Ahmed, et al.. (2023). Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma. Advances in Radiation Oncology. 8(6). 101279–101279. 4 indexed citations
8.
Kim, Y. H., M. Bagot, Pablo L. Ortiz‐Romero, et al.. (2023). LACUTAMAB IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES (MF): EFFICACY RESULTS ACCORDING TO UPDATED LYMPH NODE (LN) CLASSIFICATION IN THE TELLOMAK STUDY. Hematological Oncology. 41(S2). 196–197. 2 indexed citations
9.
Iyer, Swaminathan P., Auris Huen, Weiyun Z. Ai, et al.. (2023). Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study. Haematologica. 109(1). 209–219. 16 indexed citations
10.
Patel, Anisha B., et al.. (2022). A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes. Journal of the American Academy of Dermatology. 87(6). 1394–1395. 14 indexed citations
11.
12.
Zinzani, Pier Luigi, Pablo L. Ortiz‐Romero, Margarida Lima, & Auris Huen. (2021). Health-related quality of life effect of mogamulizumab by patient blood involvement. European Journal of Cancer. 156. S65–S66. 1 indexed citations
13.
Musiek, Amy, Kerri E. Rieger, M. Bagot, et al.. (2021). Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management. Dermatology and Therapy. 12(1). 29–40. 22 indexed citations
14.
Huen, Auris, Bradley M. Haverkos, Jasmine M. Zain, et al.. (2020). Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers. 12(8). 2293–2293. 55 indexed citations
15.
Porcu, Pierluigi, Stacie Hudgens, Sarah McCue Horwitz, et al.. (2020). Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 21(2). 97–105. 20 indexed citations
16.
Pacha, Omar, et al.. (2019). Successful treatment of cutaneous adult T-cell leukemia/lymphoma with imiquimod. JAAD Case Reports. 5(11). 979–981. 1 indexed citations
17.
Hudgens, Stacie, Pierluigi Porcu, Pietro Quaglino, et al.. (2018). Evaluation of Symptom and Side Effect Bother in Cutaneous T-Cell Lymphoma Patients Treated with Mogamulizumab or Vorinostat. Blood. 132(Supplement 1). 3592–3592. 5 indexed citations
18.
Tetzlaff, Michael T., Priyadharsini Nagarajan, Susan Y. Chon, et al.. (2017). Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. American Journal of Dermatopathology. 39(2). 121–129. 82 indexed citations
19.
20.
Wanat, Karolyn A., et al.. (2014). Pigmented Onychomatricoma: A Rare Pigmented Nail Unit Tumor Presenting as Longitudinal Melanonychia That Has Potential for Misdiagnosis as Melanoma. The Journal of Foot & Ankle Surgery. 54(4). 723–725. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeane P. Hester Breakdown of academic impact, for papers by Chih-Hsun Yang Breakdown of academic impact, for papers by Benedetta Terziroli Beretta‐Piccoli Breakdown of academic impact, for papers by Masaki Tominaga Breakdown of academic impact, for papers by É. Bégon Breakdown of academic impact, for papers by C Poynton Breakdown of academic impact, for papers by P. Papanastasiou Breakdown of academic impact, for papers by G. B. Vogelsang Breakdown of academic impact, for papers by Steve Schey Breakdown of academic impact, for papers by Vincent Descamps
Rankless by CCL
2026